These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 36586309)

  • 1. Prognostic role of annexin A2 and cancer-associated fibroblasts in advanced non-small cell lung cancer: Implication in epithelial-mesenchymal transition and gefitinib resistance.
    Ibrahim FM; Helal DS; Ali DA; Abd-Ellatif RN; Elkady AM; Sharshar R; Gharib F; Abo Elnasr M; El-Guindy DM
    Pathol Res Pract; 2023 Jan; 241():154293. PubMed ID: 36586309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer-associated fibroblasts promote epithelial-mesenchymal transition and EGFR-TKI resistance of non-small cell lung cancers via HGF/IGF-1/ANXA2 signaling.
    Yi Y; Zeng S; Wang Z; Wu M; Ma Y; Ye X; Zhang B; Liu H
    Biochim Biophys Acta Mol Basis Dis; 2018 Mar; 1864(3):793-803. PubMed ID: 29253515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epithelial-mesenchymal transition (EMT) beyond EGFR mutations per se is a common mechanism for acquired resistance to EGFR TKI.
    Weng CH; Chen LY; Lin YC; Shih JY; Lin YC; Tseng RY; Chiu AC; Yeh YH; Liu C; Lin YT; Fang JM; Chen CC
    Oncogene; 2019 Jan; 38(4):455-468. PubMed ID: 30111817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MiR-200c-3p suppression is associated with development of acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in EGFR mutant non-small cell lung cancer via a mediating epithelial-to-mesenchymal transition (EMT) process.
    Wang HY; Liu YN; Wu SG; Hsu CL; Chang TH; Tsai MF; Lin YT; Shih JY
    Cancer Biomark; 2020; 28(3):351-363. PubMed ID: 32417760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Podoplanin-positive cancer-associated fibroblasts in the tumor microenvironment induce primary resistance to EGFR-TKIs in lung adenocarcinoma with EGFR mutation.
    Yoshida T; Ishii G; Goto K; Neri S; Hashimoto H; Yoh K; Niho S; Umemura S; Matsumoto S; Ohmatsu H; Iida S; Niimi A; Nagai K; Ohe Y; Ochiai A
    Clin Cancer Res; 2015 Feb; 21(3):642-51. PubMed ID: 25388165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cause-and-Effect relationship between FGFR1 expression and epithelial-mesenchymal transition in EGFR-mutated non-small cell lung cancer cells.
    Vad-Nielsen J; Gammelgaard KR; Daugaard TF; Nielsen AL
    Lung Cancer; 2019 Jun; 132():132-140. PubMed ID: 31097086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SOX9 promotes epidermal growth factor receptor-tyrosine kinase inhibitor resistance via targeting β-catenin and epithelial to mesenchymal transition in lung cancer.
    Tripathi SK; Biswal BK
    Life Sci; 2021 Jul; 277():119608. PubMed ID: 33989664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of drug resistance for EGFR-TKIs in lung cancer via multicellular lung-on-a-chip.
    Tan J; Zhu L; Shi J; Zhang J; Kuang J; Guo Q; Zhu X; Chen Y; Zhou C; Gao X
    Eur J Pharm Sci; 2024 Aug; 199():106805. PubMed ID: 38763450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CIB2 mediates acquired gefitinib resistance by inducing ZEB1 expression and epithelial-mesenchymal transition.
    Zhou FM; Wang KK; Wang LH; Qiu JG; Wang W; Liu WJ; Wang L; Jiang BH
    Aging (Albany NY); 2024 Sep; 16(17):12277-12292. PubMed ID: 39264588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD200-positive cancer associated fibroblasts augment the sensitivity of Epidermal Growth Factor Receptor mutation-positive lung adenocarcinomas to EGFR Tyrosine kinase inhibitors.
    Ishibashi M; Neri S; Hashimoto H; Miyashita T; Yoshida T; Nakamura Y; Udagawa H; Kirita K; Matsumoto S; Umemura S; Yoh K; Niho S; Tsuboi M; Masutomi K; Goto K; Ochiai A; Ishii G
    Sci Rep; 2017 Apr; 7():46662. PubMed ID: 28429795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic silencing of miR-483-3p promotes acquired gefitinib resistance and EMT in EGFR-mutant NSCLC by targeting integrin β3.
    Yue J; Lv D; Wang C; Li L; Zhao Q; Chen H; Xu L
    Oncogene; 2018 Aug; 37(31):4300-4312. PubMed ID: 29717264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implication of epithelial-mesenchymal transition in IGF1R-induced resistance to EGFR-TKIs in advanced non-small cell lung cancer.
    Zhou J; Wang J; Zeng Y; Zhang X; Hu Q; Zheng J; Chen B; Xie B; Zhang WM
    Oncotarget; 2015 Dec; 6(42):44332-45. PubMed ID: 26554308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MiR-134/487b/655 cluster regulates TGF-β-induced epithelial-mesenchymal transition and drug resistance to gefitinib by targeting MAGI2 in lung adenocarcinoma cells.
    Kitamura K; Seike M; Okano T; Matsuda K; Miyanaga A; Mizutani H; Noro R; Minegishi Y; Kubota K; Gemma A
    Mol Cancer Ther; 2014 Feb; 13(2):444-53. PubMed ID: 24258346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypoxia Promotes Resistance to EGFR Inhibition in NSCLC Cells via the Histone Demethylases, LSD1 and PLU-1.
    Lu Y; Liu Y; Oeck S; Glazer PM
    Mol Cancer Res; 2018 Oct; 16(10):1458-1469. PubMed ID: 29934325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. STAT3 inhibitor BBI608 enhances the antitumor effect of gefitinib on EGFR-mutated non-small cell lung cancer cells.
    Wang Q; Lu B; Zhang Y; Yu J; Guo J; Zhou Q; Lv H; Sun Y
    Hum Cell; 2021 Nov; 34(6):1855-1865. PubMed ID: 34370268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interaction of FLNA and ANXA2 promotes gefitinib resistance by activating the Wnt pathway in non-small-cell lung cancer.
    Cheng L; Tong Q
    Mol Cell Biochem; 2021 Oct; 476(10):3563-3575. PubMed ID: 34018148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition.
    Soucheray M; Capelletti M; Pulido I; Kuang Y; Paweletz CP; Becker JH; Kikuchi E; Xu C; Patel TB; Al-Shahrour F; Carretero J; Wong KK; Jänne PA; Shapiro GI; Shimamura T
    Cancer Res; 2015 Oct; 75(20):4372-83. PubMed ID: 26282169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation.
    La Monica S; Madeddu D; Tiseo M; Vivo V; Galetti M; Cretella D; Bonelli M; Fumarola C; Cavazzoni A; Falco A; Gervasi A; Lagrasta CA; Naldi N; Barocelli E; Ardizzoni A; Quaini F; Petronini PG; Alfieri R
    J Thorac Oncol; 2016 Jul; 11(7):1051-63. PubMed ID: 27006151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reverse epithelial-mesenchymal transition contributes to the regain of drug sensitivity in tyrosine kinase inhibitor-resistant non-small cell lung cancer cells.
    Lee AF; Chen MC; Chen CJ; Yang CJ; Huang MS; Liu YP
    PLoS One; 2017; 12(7):e0180383. PubMed ID: 28683123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined treatment with N-acetylcysteine and gefitinib overcomes drug resistance to gefitinib in NSCLC cell line.
    Li J; Wang XH; Hu J; Shi M; Zhang L; Chen H
    Cancer Med; 2020 Feb; 9(4):1495-1502. PubMed ID: 31891230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.